IL139699A0 - Novel serpentine transmembrane antigens expressed in human cancers and uses thereof - Google Patents

Novel serpentine transmembrane antigens expressed in human cancers and uses thereof

Info

Publication number
IL139699A0
IL139699A0 IL13969999A IL13969999A IL139699A0 IL 139699 A0 IL139699 A0 IL 139699A0 IL 13969999 A IL13969999 A IL 13969999A IL 13969999 A IL13969999 A IL 13969999A IL 139699 A0 IL139699 A0 IL 139699A0
Authority
IL
Israel
Prior art keywords
strap
family
prostate
human
expressed
Prior art date
Application number
IL13969999A
Other languages
English (en)
Original Assignee
Urogenesys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Urogenesys Inc filed Critical Urogenesys Inc
Publication of IL139699A0 publication Critical patent/IL139699A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
IL13969999A 1998-06-01 1999-06-01 Novel serpentine transmembrane antigens expressed in human cancers and uses thereof IL139699A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8752098P 1998-06-01 1998-06-01
US9118398P 1998-06-30 1998-06-30
PCT/US1999/012157 WO1999062941A2 (en) 1998-06-01 1999-06-01 Serpentine transmembrane antigens expressed in human cancers and uses thereof

Publications (1)

Publication Number Publication Date
IL139699A0 true IL139699A0 (en) 2002-02-10

Family

ID=26777066

Family Applications (2)

Application Number Title Priority Date Filing Date
IL13969999A IL139699A0 (en) 1998-06-01 1999-06-01 Novel serpentine transmembrane antigens expressed in human cancers and uses thereof
IL203524A IL203524A (en) 1998-06-01 2010-01-26 Isolated steap-1 protein, a preparation that includes it, a process for its preparation and use

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL203524A IL203524A (en) 1998-06-01 2010-01-26 Isolated steap-1 protein, a preparation that includes it, a process for its preparation and use

Country Status (13)

Country Link
US (10) US6329503B1 (https=)
EP (2) EP2080802B1 (https=)
JP (5) JP4855577B2 (https=)
AT (1) ATE437947T1 (https=)
AU (1) AU757698C (https=)
CA (1) CA2328989C (https=)
CY (1) CY1109509T1 (https=)
DE (1) DE69941187D1 (https=)
DK (1) DK1086223T3 (https=)
ES (2) ES2629442T3 (https=)
IL (2) IL139699A0 (https=)
PT (1) PT1086223E (https=)
WO (1) WO1999062941A2 (https=)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136311A (en) 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
US20020187472A1 (en) * 2001-03-09 2002-12-12 Preeti Lal Steap-related protein
US20030149531A1 (en) * 2000-12-06 2003-08-07 Hubert Rene S. Serpentine transmembrane antigens expressed in human cancers and uses thereof
US6833438B1 (en) 1999-06-01 2004-12-21 Agensys, Inc. Serpentine transmembrane antigens expressed in human cancers and uses thereof
US20060052321A1 (en) * 2002-04-05 2006-03-09 Raitano Arthur B Nucleic acid and corresponding protein entitled 98P4B6 useful in treatment and detection of cancer
AU757698C (en) 1998-06-01 2004-04-08 Agensys, Inc. Novel serpentine transmembrane antigens expressed in human cancers and uses thereof
US20040141975A1 (en) 1998-06-01 2004-07-22 Raitano Arthur B. Nucleic acid and corresponding protein entitled 98P4B6 useful in treatment and detection of cancer
US20040048798A1 (en) * 1999-06-01 2004-03-11 Raitano Arthur B. Nucleic acid and corresponding protein entitle 98P4B6 useful in treatment and detection of cancer
US6902892B1 (en) 1998-10-19 2005-06-07 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating prostate cancer
WO2000071711A2 (en) * 1999-05-20 2000-11-30 Fahri Saatcioglu Differentially expressed genes in prostate cancer
DK1244705T3 (da) * 1999-12-06 2010-05-31 Agensys Inc Serpentintransmembrane antigener udtryk i human prostatacancere og anvendelser deraf
TWI335336B (https=) * 2000-02-10 2011-01-01 Abbott Gmbh & Co Kg
US7611892B2 (en) * 2000-03-24 2009-11-03 President And Fellows Of Harvard College Prostate-specific or testis-specific nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
JP2004521602A (ja) * 2000-03-24 2004-07-22 ファハリ サッチオグリュ 前立腺特異的または精巣特異的な新規の核酸分子、ポリペプチド、ならびに診断法および治療法
US7189565B2 (en) * 2001-03-23 2007-03-13 Fahri Saatcioglu Prostate-specific or testis-specific nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
EP1360203B1 (en) * 2001-01-17 2008-12-24 Intreat Pty Limited Antibodies to non-functional p 2 x 7 receptor diagnosis and treatment of cancers and other conditions
US20030194798A1 (en) 2001-05-24 2003-10-16 Surber Mark W. Minicell compositions and methods
ES2537074T3 (es) * 2001-09-06 2015-06-02 Agensys, Inc. Ácido nucleico y proteína correspondiente denominados STEAP-1 útiles en el tratamiento y la detección de cáncer
US7494646B2 (en) 2001-09-06 2009-02-24 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
AU2002360670A1 (en) * 2001-12-19 2003-07-09 Wilk Patent Development Corporation Method and related composition employing nanostructures
CA2517027A1 (en) 2002-02-25 2003-09-04 Vaxiion Therapeutics, Inc. Minicell compositions and methods
AU2003256912A1 (en) * 2002-08-16 2004-03-03 Yeda Research And Development Co. Ltd. Tumor associated antigen, peptides thereof, and use of same as anti-tumor vaccines
JP5840351B2 (ja) * 2002-09-06 2016-01-06 アジェンシス，インコーポレイテッド 癌の処置および検出において有用な９８ｐ４ｂ６と称される、核酸および対応タンパク質
US7498298B2 (en) 2003-11-06 2009-03-03 Seattle Genetics, Inc. Monomethylvaline compounds capable of conjugation to ligands
ES2443996T3 (es) 2004-04-22 2014-02-21 Agensys, Inc. Anticuerpos y moléculas derivadas de los mismos que se unen a proteínas STEAP-1
US8765164B2 (en) * 2005-10-21 2014-07-01 Kenneth W. Carpenter Poly(ester urea) polymers and methods of use
WO2007109321A2 (en) 2006-03-20 2007-09-27 The Regents Of The University Of California Engineered anti-prostate stem cell antigen (psca) antibodies for cancer targeting
JP2010505426A (ja) * 2006-10-10 2010-02-25 バイオスセプター インターナショナル リミテッド 非機能性ｐ２ｘ７受容体に対する抗体を産生するハイブリドーマ
WO2008043146A1 (en) * 2006-10-10 2008-04-17 Biosceptre International Limited Antibodies against non functional p2x7 receptor
KR20140116546A (ko) 2006-10-27 2014-10-02 제넨테크, 인크. 항체 및 면역접합체 및 이들의 용도
DK2474557T3 (da) 2007-07-16 2014-11-10 Genentech Inc Anti-CD79b-antistoffer og immunkonjugater og fremgangsmåder til anvendelse
NZ583318A (en) 2007-07-16 2012-07-27 Genentech Inc Humanized anti-cd79b antibodies and immunoconjugates and methods of use
EP4464384A3 (en) 2007-08-17 2025-01-08 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
US8940298B2 (en) 2007-09-04 2015-01-27 The Regents Of The University Of California High affinity anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting and detection
AU2008299594B2 (en) 2007-09-14 2013-10-03 Biosceptre International Limited Purinergic (P2X) receptors in extra-cellular body fluid
AU2008299593B2 (en) 2007-09-14 2013-04-18 Biosceptre International Limited Novel P2X7 epitopes
WO2009046294A2 (en) * 2007-10-03 2009-04-09 Cornell University Treatment of proliferative disorders using antibodies to psma
SG187517A1 (en) 2008-01-31 2013-02-28 Genentech Inc Anti-cd79b antibodies and immunoconjugates and methods of use
BRPI0915367B8 (pt) 2008-07-04 2021-05-25 Biosceptre International Ltd peptídeo anti-p2x7
EP2398504B1 (en) 2009-02-17 2018-11-28 Cornell Research Foundation, Inc. Methods and kits for diagnosis of cancer and prediction of therapeutic value
ES2904911T3 (es) 2009-08-20 2022-04-06 Biosceptre Aust Pty Ltd Anticuerpos anti-receptor P2X7 y fragmentos de los mismos
CA2782333C (en) 2009-12-02 2019-06-04 Imaginab, Inc. J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use
JP5992831B2 (ja) 2009-12-24 2016-09-14 バイオセプター・（オーストラリア）・ピーティーワイ・リミテッド 非機能性オリゴマーｐ２ｘ７受容体に対する抗体
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
RU2613886C2 (ru) 2010-06-03 2017-03-21 Дженентек, Инк. Антитела и иммуноконъюгаты, визуализируемые при помощи иммуно-позитрон-эмиссионной томографии, и способы их применения
CN106310245A (zh) 2010-09-10 2017-01-11 生物权威(澳大利亚)有限责任公司 陪伴动物治疗
WO2012057765A1 (en) 2010-10-28 2012-05-03 The Board Of Regents Of The University Of Texas System Recombinant anti-cd19 monoclonal antibodies
CA2817709C (en) 2010-11-12 2021-06-01 The Trustees Of The University Of Pennsylvania Consensus prostate antigens, nucleic acid molecule encoding the same and vaccine and uses comprising the same
AU2015261742B2 (en) * 2010-11-12 2017-10-26 Inovio Pharmaceuticals, Inc. Consensus prostate antigens nucleic acid molecule encoding the same and vaccine and uses comprising the same
ES2720659T3 (es) 2011-02-15 2019-07-23 Vaxiion Therapeutics Llc Composiciones terapéuticas y métodos para la administración dirigida, mediante minicélulas bacterianas, de moléculas bioactivas basadas en moléculas dirigidas que contienen Fc y anticuerpos
US9566318B2 (en) 2011-07-01 2017-02-14 Biosceptre (Aust) Pty Ltd Combination therapy
BR112014012882A2 (pt) 2011-11-29 2017-06-13 Genentech Inc método, anticorpo, polinucleotídeo, célula hospedeira, linhagem celular de hibridoma, uso do anticorpo e kit
BR112015011118B1 (pt) 2012-11-15 2022-12-13 Endocyte, Inc Conjugado; composição farmacêutica; e uso de um conjugado
MX2015014666A (es) 2013-04-17 2016-03-01 Pfizer Derivados de n-piperidin-3-ilbenzamida para tratar enfermedades cardiovasculares.
KR101782623B1 (ko) 2013-07-10 2017-09-28 서울대학교산학협력단 복합 막횡단 단백질의 세포막외 펩타이드 항원 및 그의 용도
LT4095130T (lt) 2013-10-18 2024-04-25 Novartis Ag Žymėti prostatos specifinio membranos antigeno (psma) inhibitoriai, jų naudojimas kaip vizualizavimo medžiagų ir farmacinių medžiagų prostatos vėžiui gydyti
BR112016010927A2 (pt) 2013-11-14 2017-08-08 Endocyte Inc Conjugado de fórmula
PT3262071T (pt) 2014-09-23 2020-06-16 H Hoffnabb La Roche Ag Métodos de utilização de imunoconjugados anti-cd79b
US10188759B2 (en) 2015-01-07 2019-01-29 Endocyte, Inc. Conjugates for imaging
CN108064246A (zh) 2015-06-15 2018-05-22 基因泰克公司 抗体和免疫结合物
WO2017027325A1 (en) 2015-08-07 2017-02-16 Imaginab, Inc. Antigen binding constructs to target molecules
US10588953B2 (en) 2015-12-18 2020-03-17 Agilvax, Inc. Compositions and methods related to xCT peptides
MX2019003325A (es) * 2016-09-23 2019-08-05 Regeneron Pharma Anticuerpos anti-steap2, conjugados anticuerpo-farmaco, y moleculas de fijacion al antigeno biespecificas que se fijan a steap2 y cd3, y usos de estos.
EP3548515B1 (en) 2016-12-01 2026-01-21 Regeneron Pharmaceuticals, Inc. Radiolabeled anti-pd-l1 antibodies for immuno-pet imaging
WO2018147960A1 (en) 2017-02-08 2018-08-16 Imaginab, Inc. Extension sequences for diabodies
SG11201909218RA (en) 2017-04-03 2019-11-28 Hoffmann La Roche Antibodies binding to steap-1
EP3618869A4 (en) 2017-05-01 2021-01-20 Agilvax, Inc. COMPOSITIONS AND PROCEDURES RELATED TO XCT ANTIBODIES
FI3635009T3 (fi) 2017-06-07 2026-04-07 Regeneron Pharma Koostumuksia ja menetelmiä entsyymien internalisoimiseksi
US12208102B2 (en) 2018-04-17 2025-01-28 Endocyte, Inc. Methods of treating cancer
EP3793591A1 (en) 2018-05-17 2021-03-24 Regeneron Pharmaceuticals, Inc. Anti-cd63 antibodies, conjugates, and uses thereof
TW202519260A (zh) 2018-07-02 2025-05-16 美商安進公司 抗steap1抗原結合蛋白
EA202190304A1 (ru) * 2018-07-18 2022-01-21 Эмджен Инк. Химерные рецепторы к steap1 и способы их применения
CN114096264B (zh) 2019-05-20 2025-03-14 因多塞特股份有限公司 制备psma缀合物的方法

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5851764A (en) * 1990-10-25 1998-12-22 The Trustees Of Columbia University In The City Of New York Human prostate tumor inducing gene-1 and uses thereof
US5489525A (en) 1992-10-08 1996-02-06 The United States Of America As Represented By The Department Of Health And Human Services Monoclonal antibodies to prostate cells
WO1995014772A1 (en) 1993-11-12 1995-06-01 Kenichi Matsubara Gene signature
WO1997035616A1 (en) * 1996-03-25 1997-10-02 Pacific Northwest Cancer Foundation Monoclonal antibodies specific for the extracellular domain of prostate specific membrane antigen
US5859045A (en) 1996-05-08 1999-01-12 Novo Nordisk A/S Novo Alle Crystalline -! 3R 4R-trans-7 methoxy 2,2-dimethyl1-3-phenyl 1-4 4-12 pyrrolidin-1 -Y1!ethoxyl 1!chromane hydrogen fumarate
EP0974057B1 (en) * 1996-07-15 2005-09-21 Mayo Foundation For Medical Education And Research Methods to detect hk2 polypeptides
US5824504A (en) 1996-09-26 1998-10-20 Elshourbagy; Nabil A. Human 7-transmembrane receptor and DNA
DE19641560A1 (de) * 1996-10-09 1998-04-16 Boehringer Mannheim Gmbh Monoklonale Antikörper gegen einen Komplex aus humanem ACT und einer Serinprotease
ES2290964T3 (es) 1996-10-15 2008-02-16 The Regents Of The University Of California Modelos animales de la evolucion del cancer de prostata humano.
WO1998018489A1 (en) 1996-10-30 1998-05-07 The Uab Research Foundation Enhancement of tumor cell chemosensitivity and radiosensitivity using single chain intracellular antibodies
EP1500329B1 (en) 1996-12-03 2012-03-21 Amgen Fremont Inc. Human antibodies that specifically bind human TNF alpha
TR199902053T2 (xx) 1997-02-25 2000-04-21 Corixa Corporation Prostat kanserinin immunoterapisine y�nelik bile�ikler ve bunlar�n kullan�lmas�na matuf metodlar.
WO1998037418A2 (en) * 1997-02-25 1998-08-27 Corixa Corporation Compounds for immunodiagnosis of prostate cancer and methods for their use
US6800746B2 (en) 1997-02-25 2004-10-05 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
EP0983357A1 (en) 1997-05-23 2000-03-08 Biogen, Inc. Modulators of tissue regeneration
EP1000148A2 (en) 1997-08-01 2000-05-17 Genset 5' ESTs FOR SECRETED PROTEINS EXPRESSED IN PROSTATE
DK1000146T3 (da) 1997-08-01 2007-01-08 Serono Genetics Inst Sa 5' EST'er for non-vævsspecifikke secernerede proteiner
JPH11164691A (ja) 1997-10-03 1999-06-22 Rikagaku Kenkyusho 胚盤胞ｃＤＮＡ
US20030060612A1 (en) 1997-10-28 2003-03-27 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US6255049B1 (en) * 1998-02-27 2001-07-03 The Trustees Of Columbia University In The City Of New York Detection of metastatic cancer cells using PCTA-1
US20030064397A1 (en) 1998-05-22 2003-04-03 Incyte Genomics, Inc. Transmembrane protein differentially expressed in prostate and lung tumors
US6048970A (en) 1998-05-22 2000-04-11 Incyte Pharmaceuticals, Inc. Prostate growth-associated membrane proteins
AU757698C (en) 1998-06-01 2004-04-08 Agensys, Inc. Novel serpentine transmembrane antigens expressed in human cancers and uses thereof
CN100419079C (zh) 1998-07-14 2008-09-17 科里克萨有限公司 用于治疗和诊断前列腺癌的组合物和方法
EP1140970A4 (en) 1998-12-17 2003-10-22 Human Genome Sciences Inc 47 HUMAN SECRETED PROTEINS
EP1179541B1 (en) 1999-04-28 2004-06-16 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting VEGF
JP2003502061A (ja) 1999-06-11 2003-01-21 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ４８個のヒト分泌タンパク質
JP2003527089A (ja) 1999-08-17 2003-09-16 インサイト・ゲノミックス・インコーポレイテッド 膜関連タンパク質
GB2354821A (en) 1999-09-29 2001-04-04 Dine O Quick Threshold crossing counter
AU7994200A (en) 1999-10-04 2001-05-10 Corixa Corporation Compositions and methods for therapy and diagnosis of prostate cancer
UA74798C2 (uk) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
EP1230364A2 (en) 1999-11-12 2002-08-14 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
DK1244705T3 (da) 1999-12-06 2010-05-31 Agensys Inc Serpentintransmembrane antigener udtryk i human prostatacancere og anvendelser deraf
IL150732A0 (en) 2000-01-14 2003-02-12 Corixa Corp Prostate specific polypeptides, polynucleotides that encode said polypeptides and pharmaceutical compositions containing the same
CA2399776A1 (en) 2000-02-03 2001-08-09 Hyseq, Inc. Novel nucleic acids and polypeptides
WO2001057252A2 (en) 2000-02-04 2001-08-09 Aeomica, Inc. Methods and apparatus for high-throughput detection and characterization of alternatively spliced genes
WO2001060860A2 (en) 2000-02-17 2001-08-23 Millennium Predictive Medicine, Inc. Genes differentially expressed in human prostate cancer and their use
JP2004521602A (ja) 2000-03-24 2004-07-22 ファハリ サッチオグリュ 前立腺特異的または精巣特異的な新規の核酸分子、ポリペプチド、ならびに診断法および治療法
CA2403909A1 (en) 2000-03-27 2001-10-04 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6436703B1 (en) 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
EP1358349A2 (en) 2000-06-05 2003-11-05 Avalon Pharmaceuticals Cancer gene determination and therapeutic screening using signature gene sets
US20020177552A1 (en) 2000-06-09 2002-11-28 Corixa Corporation Compositions and methods for the therapy and diagnosis of colon cancer
AU2002210791A1 (en) 2000-07-28 2002-02-13 Compugen Inc. Oligonucleotide library for detecting rna transcripts and splice variants that populate a transcriptome
KR20030029847A (ko) 2000-08-24 2003-04-16 제넨테크, 인크. 종양의 진단 및 치료를 위한 조성물 및 방법
AU2002215345A1 (en) 2000-10-13 2002-04-22 Eos Biotechnology, Inc. Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer
EP1661986A1 (en) 2000-11-17 2006-05-31 Nuvelo, Inc. Nucleic acids and polypeptides enocoded thereby that are member of the kallikrein gene familyNovel nucleic acids and polypeptides
WO2002057303A2 (en) 2001-01-12 2002-07-25 Hybrigenics Protein-protein interactions between shigella flexneri polypeptides and mammalian polypeptides
CA2441417A1 (en) 2001-03-21 2002-11-14 Human Genome Sciences, Inc. Human secreted proteins
WO2003009814A2 (en) 2001-07-25 2003-02-06 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer
US7494646B2 (en) * 2001-09-06 2009-02-24 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
ES2537074T3 (es) 2001-09-06 2015-06-02 Agensys, Inc. Ácido nucleico y proteína correspondiente denominados STEAP-1 útiles en el tratamiento y la detección de cáncer
EP1308459A3 (en) 2001-11-05 2003-07-09 Research Association for Biotechnology Full-length cDNA sequences
US6918525B2 (en) * 2003-05-23 2005-07-19 Worktools, Inc. Spring energized desktop stapler
ES2443996T3 (es) * 2004-04-22 2014-02-21 Agensys, Inc. Anticuerpos y moléculas derivadas de los mismos que se unen a proteínas STEAP-1
KR101270829B1 (ko) 2004-09-23 2013-06-07 제넨테크, 인크. 시스테인 유전자조작 항체 및 접합체
US7056186B1 (en) * 2005-04-06 2006-06-06 Weyenberg Karey M Cleavage-enhancing foundation garment

Also Published As

Publication number Publication date
US7928201B2 (en) 2011-04-19
US20060147951A1 (en) 2006-07-06
DK1086223T3 (da) 2009-11-30
US20050064445A1 (en) 2005-03-24
US7642054B2 (en) 2010-01-05
US7053186B2 (en) 2006-05-30
JP2017079748A (ja) 2017-05-18
AU757698C (en) 2004-04-08
EP1086223A2 (en) 2001-03-28
ES2629442T3 (es) 2017-08-09
US20100173297A1 (en) 2010-07-08
EP2080802A3 (en) 2009-08-05
US20050202454A1 (en) 2005-09-15
IL203524A (en) 2013-06-27
US7575749B2 (en) 2009-08-18
CA2328989C (en) 2012-02-07
EP2080802A2 (en) 2009-07-22
WO1999062941A9 (en) 2000-09-14
JP2012050434A (ja) 2012-03-15
JP4855577B2 (ja) 2012-01-18
JP4871341B2 (ja) 2012-02-08
US20110318371A1 (en) 2011-12-29
CY1109509T1 (el) 2014-08-13
US7968307B2 (en) 2011-06-28
JP2009106284A (ja) 2009-05-21
US6887975B2 (en) 2005-05-03
US20100190962A1 (en) 2010-07-29
ES2329851T3 (es) 2009-12-01
ATE437947T1 (de) 2009-08-15
JP6371362B2 (ja) 2018-08-08
US20070104720A1 (en) 2007-05-10
WO1999062941A2 (en) 1999-12-09
EP1086223B1 (en) 2009-07-29
PT1086223E (pt) 2009-11-03
US7166714B2 (en) 2007-01-23
JP2014239695A (ja) 2014-12-25
CA2328989A1 (en) 1999-12-09
AU4326299A (en) 1999-12-20
US7611904B2 (en) 2009-11-03
JP2002517184A (ja) 2002-06-18
US20030045682A1 (en) 2003-03-06
WO1999062941A8 (en) 2000-08-03
JP5683414B2 (ja) 2015-03-11
WO1999062941A3 (en) 2000-04-06
US6329503B1 (en) 2001-12-11
AU757698B2 (en) 2003-03-06
DE69941187D1 (de) 2009-09-10
US8414898B2 (en) 2013-04-09
EP2080802B1 (en) 2017-03-29
US20030055217A1 (en) 2003-03-20

Similar Documents

Publication Publication Date Title
IL139699A0 (en) Novel serpentine transmembrane antigens expressed in human cancers and uses thereof
IL199275A0 (en) Serpentine transmembrane sntigens expressed in human prostate cancers and uses thereof
BR0009964A (pt) Peptìdios artificiais com atividade desuperfìcie e sua utilização na preparação de surfactante artificial
FI964766A0 (fi) Keuhkopintaproteiinin SP-C synteettiset peptidianalogit
CA2092533A1 (en) Nucleotide sequences coding for a human protein with angiogenesis regulative properties
AU2001254624A1 (en) Human coagulation factor vii variants
MX336118B (es) Expresion hibrida y en tandem de proteinas de neisseria.
RU2002124123A (ru) Модифицированный фактор viii
EP2028270A3 (en) Modified recombinant vaccinia viruses and other microorganisms, uses thereof
DE69926647D1 (de) Durch molekulares pathogenicid vermittelte krankheitsresistenz in pflanzen
PL336295A1 (en) Modified tnfalpha molecule, dna encoding such molecule and vaccine comprising such tnfalpha molecule and such dna
FR2649982B1 (fr) Membrane biologique artificielle
ES2060803T3 (es) Soporte biologico para cultivos celulares constituido por proteinas plasmaticas coaguladas por trombina, su utilizacion para el cultivo de los queratinocitos, su recuperacion y su transporte con fines de utilizacion terapeutica.
NO971341L (no) Promoter for reseptor tyrosinkinase TIE
NZ333203A (en) Tumour antigen proteins, genes thereof, and tumour antigen peptides
DK1040191T3 (da) RANTES-mutanter og terapeutiske anvendelser heraf
WO2002022784A3 (en) Expression, preparation, uses, and sequence of recombinantly-derived soluble hla-g
PL353872A1 (en) Antitumor antibodies, proteins, and uses thereof
WO2000004157A3 (en) Cloning and characterisation of novel mammalian peptidases
IL150045A0 (en) Compositions and methods for detecting stress-inducible proteins
Niemčić The pokladarsko kolo on the island of Lastovo
ES8705466A1 (es) Un metodo para la preparacion del factor nkbs regulador del cancer humano.
WO2001082948A3 (en) Uses of tgap7 for the modulation of leucocyte activation
AU2001281943A1 (en) The t-cell protein (tzon7), peptides and antibodies derived therefrom and uses thereof
UA40172A (uk) Спосіб пластики вихідного тракту правого шлуночка і легеневої артерії при радикальній корекції тетради фалло

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
EXP Patent expired